# 2025-23252: FDA Updates: Real-Life Proof for Medical Gadgets

2025-23252, Use of Real-World Evidence To Support Regulatory Decision-Making for Medical Devices; Guidance for Industry and Food and Drug Administration Staff; Availability, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2025-12-18, effective 2025-12-18 (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2025-23252
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-23252
- Title: Use of Real-World Evidence To Support Regulatory Decision-Making for Medical Devices; Guidance for Industry and Food and Drug Administration Staff; Availability
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 59127
- Published: 2025-12-18
- Effective: 2025-12-18
- Comments close: not stated
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA Updates: Real-Life Proof for Medical Gadgets

## Summary

The FDA just released updated rules on how real-world data can help approve medical devices faster and smarter. This affects medical device makers and FDA staff by giving clearer, better ways to use everyday health info for decisions. The new guidance starts December 18, 2025, aiming to speed up approvals without extra costs.

## Abstract

The Food and Drug Administration (FDA, the Agency, or we) is announcing the availability of a final guidance entitled "Use of Real- World Evidence to Support Regulatory Decision-Making for Medical Devices." FDA is issuing this guidance to clarify how FDA evaluates real-world data (RWD) to determine whether they are of sufficient quality for generating real-world evidence (RWE) that can be used in FDA regulatory decision-making for medical devices. This final guidance supersedes the final guidance, "Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices," issued August 31, 2017, and provides expanded and updated recommendations.

## Effects PRIA read

- Clarifies use of real‑world data: benefit, medium. If you are a medical device sponsor or manufacturer, FDA issued final guidance on December 18, 2025 that explains how FDA evaluates real‑world data (RWD) to determine whether they are good enough to generate real‑world evidence (RWE) for regulatory decision‑making. The guidance updates and expands…
- EUA and CLIA data usability clarified: benefit, low. The guidance provides additional clarity about using clinical data collected from devices authorized under an Emergency Use Authorization (EUA) and describes what types of information could be applicable to support Clinical Laboratory Improvement Amendments (CLIA) determinations, such as a Waiver b…
- 60‑day operational transition period: benefit, low. FDA recognizes that the Agency and industry may need up to 60 days to operationalize the recommendations in this final guidance. For submissions pending after publication on December 18, 2025, and for submissions received within 60 days following that date, FDA generally does not expect sponsors to…
- No new paperwork collections required: benefit, low. The guidance states it contains no new collection of information under the Paperwork Reduction Act and instead refers to previously approved FDA collections with listed OMB control numbers. That means the guidance itself does not add new PRA reporting requirements.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2025-23252 on federalregister.gov](https://www.federalregister.gov/documents/2025/12/18/2025-23252/use-of-real-world-evidence-to-support-regulatory-decision-making-for-medical-devices-guidance-for)
- [2025-23252 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-12-18/pdf/2025-23252.pdf)

## Related
- [Previous: 2025-23251, Submission for OMB Review; 30-Day Comment Request; Special Volunteer and Guest…](https://policyrisk.com/federal-register/2025-23251)
- [Next: 2025-23255, Performance Review Board Membership](https://policyrisk.com/federal-register/2025-23255)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-23252 (as of 2026-06-08).
